News and Announcements
AIMEDICS – CEO Interview
- Published September 24, 2012 10:56AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
AIMEDICS has developed the HypoMon which is the world’s first non-invasive night time low blood glucose management system. More than 11 million diabetic insulin users in the developed world suffer from bouts of dangerously low blood glucose several nights per month. Independent USA market research indicates that the HypoMon is a unique product addressing a recognised unmet need with a market opportunity exceeding $2 billion pa.
Executive Interviews
Why Are Fewer Companies Going Public?
The number of companies listing on the ASX has declined, driven by access to private capital, regulatory burdens, and market volatility. However, public markets still offer liquidity, visibility, and robust capital-raising opportunities.
A Message to Founders: A Shared Journey to 2025 – A Once in a Generation Opportunity
As we close this challenging year, let’s reflect on the resilience, lessons, and growth that brought us here. Founders, 2025 is your golden opportunity to innovate, scale, and thrive. Set your strategy, rest, and prepare to sprint into a year of unparalleled possibilities.
From Trash to Treasure: Inside Australia’s First Commercial Waste-to-Hydrogen Facility
Greenhill Energy’s pioneering waste-to-hydrogen facility marks a significant step in sustainable energy. This Australian innovation is transforming waste management into clean, valuable hydrogen, presenting investors with a unique, forward-thinking opportunity.
Backed By Leading Investment Groups and Family Offices
